PubRank

Jonathan R Brody

Author PubWeight™ 56.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009 3.15
2 Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther 2006 2.70
3 Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 2011 2.67
4 Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010 1.99
5 In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005 1.74
6 Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther 2008 1.74
7 Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012 1.63
8 Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 2012 1.55
9 Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther 2004 1.48
10 The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009 1.41
11 Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004 1.32
12 High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 2007 1.19
13 Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 2011 1.18
14 Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 2008 1.18
15 Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008 1.17
16 A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 2012 1.15
17 Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009 1.11
18 Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther 2008 1.10
19 HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg 2010 1.10
20 Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle 2011 1.07
21 HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res 2014 1.05
22 Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 2008 1.04
23 Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 2010 1.03
24 A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008 1.02
25 Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006 0.97
26 HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther 2012 0.95
27 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem 2012 0.93
28 Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol Cancer Res 2013 0.92
29 Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res 2013 0.92
30 Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv 2010 0.91
31 pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One 2010 0.90
32 Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res 2013 0.89
33 Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther 2010 0.89
34 HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol 2013 0.89
35 Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer 2012 0.86
36 Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 2007 0.85
37 Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. J Gastroenterol Hepatol 2009 0.84
38 High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res 2007 0.84
39 Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. BMC Genet 2006 0.83
40 Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma. HPB (Oxford) 2009 0.83
41 Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays. Methods Mol Biol 2015 0.79
42 Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box". Cancer J 2012 0.79
43 Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat 2004 0.79
44 Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. J Surg Res 2011 0.78
45 The 'RNA-binding ome': future implications for chemotherapeutic efficacy. Future Oncol 2009 0.78
46 Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma. Oncology (Williston Park) 2015 0.78
47 CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy. Cancer Biol Ther 2010 0.78
48 Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature. J Gastrointest Surg 2011 0.77
49 Upgrading gemcitabine with recycled kinase inhibitors. Cell Cycle 2014 0.76
50 Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg 2016 0.75
51 Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology (Williston Park) 2017 0.75
52 No K01 offered from the NCI What's the message? Cancer Biol Ther 2007 0.75